Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

Protein engineering, design & selection : PEDS - 1 Oct 2016

Schlothauer Tilman, Herter Sylvia, Koller Claudia Ferrara, Grau-Richards Sandra, Steinhart Virginie, Spick Christian, Kubbies Manfred, Klein Christian, Umaña Pablo, Mössner Ekkehard

Abstract excerpt

Recombinant human IgG antibodies (hIgGs) completely devoid of binding to Fcγ receptors (FcγRs) and complement protein C1q, and thus with abolished immune effector functions, are of use for various therapeutic applications in order to reduce FcγR activation and Fc-mediated toxicity. Fc engineering approaches described to date only partially achieve this goal or employ a large number of mutations, which may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Conserved Sequence
Share to Glycosylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to Immunoglobulin G

Share to Platelet Aggregation

Share to Protein Engineering

Share to Receptors, Complement

Share to Receptors, IgG

Source

Identifiers

PMID: 27578889
DOI: 10.1093/protein/gzw040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.PMID 27578889Read ↗

Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing VariantsSemantic proximity Read ↗

Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune FunctionalitySemantic proximity Read ↗

Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.Semantic proximity Read ↗

Optimizing therapeutic antibody function: progress with Fc domain engineering.Semantic proximity Read ↗

Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector FunctionsSemantic proximity Read ↗

A Primer for Junior Trainees: The Structure, Binding, and Therapeutic Applications of Immunoglobulin GSemantic proximity Read ↗

Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.Semantic proximity Read ↗

Antibody therapeutics:Semantic proximity Read ↗

Mapping affinity and allostery in human IgG antibody Fc region-Fc γ receptor interactionsSemantic proximity Read ↗

IgG Subclasses and Allotypes: From Structure to Effector FunctionsSemantic proximity Read ↗

Structure-Function Analysis of the FCRL5-IgG1 Fc Complex Reveals an Unappreciated Effect of Fc-Silent Antibodies on B cellsSemantic proximity Read ↗

Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.